Luminex Confirms Effectiveness of xTAG® Respiratory Viral Panel for Swine Flu Surveillance

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today issued a follow-up statement to an announcement on Monday, April 27, 2009, confirming that the xTAG® Respiratory Viral Panel (RVP) assay has been demonstrated to be effective in surveillance of swine flu. Specifically, Luminex has verified through testing on confirmed swine flu-positive samples that the xTAG RVP assay will correctly identify these samples as positive for influenza A and negative for common seasonal flu strains of influenza A H1 and H3. This is the expected outcome for novel influenza A strains which prompts follow-up testing by state or federal public health labs with assays such as the Centers for Disease Control (CDC) swine flu assay.

Over the past several days, scientists at Luminex have reviewed data provided by public health laboratories in Canada and the United States, and have internally generated data that indicate that the xTAG RVP assay is effective in swine flu surveillance. As a result of xTAG RVP’s unique ability to simultaneously identify the influenza A virus matrix gene and specific common seasonal flu subtypes of that virus, H1 and H3, xTAG RVP can be an effective tool in a public health setting. In this environment, a test with this capability could prove to be essential for an effective surveillance program.

“xTAG RVP’s ability to determine if a patient is carrying a normal, seasonal respiratory virus or an unknown H1 flu A virus can be a critical first line of defense in separating standard respiratory infections from swine flu cases,” said Patrick J. Balthrop, Sr., president and chief executive officer of Luminex. “Luminex is very pleased to have the opportunity to have a positive impact in this surveillance effort. This is a critical situation, and we are hopeful that xTAG RVP will be useful in protecting the public health. Our investment in the research and development of unique, innovative products such as xTAG RVP has been a top priority for our company. We look forward to continuing to work with public health officials and health care professionals, including our customers, to deliver quality results and improve the lives of people worldwide.”

xTAG RVP was cleared by the FDA in January 2008, and is the only commercially-available test that can simultaneously detect 12 respiratory viruses and subtypes, including Flu A with subtyping, at the DNA/RNA level. During an outbreak this test can provide the physician with valuable information as most patients will be positive for one of the more common viruses included in the panel. In the event that a rare Flu A virus is detected, as included in the xTAG RVP labeling and package insert reviewed and cleared by FDA, samples that test positive for total Flu A but are not positive for the included seasonal flu subtypes should be referred to a public health lab such as CDC for follow up.

Luminex is continuing to work with many current customers, including public health laboratories and officials to gather additional data and samples to further confirm their findings.

xTAG RVP is available in the U.S. through Luminex Molecular Diagnostics, Fisher HealthCare and Abbott Laboratories. It is available worldwide from Luminex Molecular Diagnostics and Abbott.

For more information on xTAG RVP, please visit www.luminexcorp.com/rvp.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company’s xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company’s xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.

Statements made in this release that express Luminex’s or management’s intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will,” “could,” “should” and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex’s actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex’s products, the Company’s dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company’s revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex’s ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company’s strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading “Risk Factors” in Luminex’s Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.